Comparative Pharmacology
Head-to-head clinical analysis: NUTROPIN AQ PEN versus ZOMACTON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUTROPIN AQ PEN versus ZOMACTON.
NUTROPIN AQ PEN vs ZOMACTON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human growth hormone (somatropin) that binds to growth hormone receptors, activating JAK2/STAT5 signaling, promoting linear growth, increasing IGF-1 synthesis, and enhancing protein synthesis, lipolysis, and carbohydrate metabolism.
ZOMACTON is a recombinant human growth hormone that binds to growth hormone receptors on cell surfaces, activating intracellular signaling cascades (primarily JAK-STAT pathway) leading to increased IGF-1 production, which mediates growth and metabolic effects including linear growth, protein synthesis, and lipolysis.
0.2 mg subcutaneously 3 times per week for growth hormone deficiency; dose adjusted based on patient response and serum IGF-1 levels.
Intramuscular or subcutaneous injection: 0.1-0.3 mg/kg/day (up to 0.6 mg/kg/day) divided into 1-2 doses. Typical adult dose for growth hormone deficiency: 0.2 mg/kg/day subcutaneously.
None Documented
None Documented
Terminal elimination half-life is approximately 2.6 to 3.6 hours after subcutaneous administration. In clinical practice, this short half-life supports daily dosing.
Terminal elimination half-life: 2-3 hours after subcutaneous administration; clinically, this necessitates daily or more frequent dosing.
Primarily renal (glomerular filtration and tubular reabsorption); less than 0.1% of the administered dose is excreted unchanged in urine. The majority is metabolized in the liver and kidneys via proteolysis, and metabolites are excreted renally.
Renal: nearly 100% of absorbed dose, mostly as intact hormone; negligible biliary/fecal elimination.
Category C
Category C
Growth Hormone
Growth Hormone